Branching morphogenesis of human mammary epithelial cells in collagen gels.
To study the morphogenesis of human epithelial cells in vitro we have used a three-dimensional collagen matrix and a newly developed mammary epithelial cell line, 1-7 HB2. In standard medium 1-7 HB2 cells formed compact balls/spheres inside collagen type I gels, while cocultivation with various fibroblast cell lines or growth in fibroblast-conditioned media resulted in the appearance of branching structures. At least two different soluble factors secreted by fibroblasts were found to be implicated in the branching morphogenesis. Firstly, hepatocyte growth factor/scatter factor could induce branching in a concentration-dependent manner. Moreover, a polyclonal serum against hepatocyte growth factor/scatter factor completely inhibited the branching morphogenesis induced by medium conditioned by MRC-5 fibroblast cells. In contrast, a morphogenetic activity secreted by human foreskin fibroblasts was identified that appears to be different from hepatocyte growth factor/scatter factor and from a number of other well-characterized growth factors or cytokines. This model system has been used to examine the role of integrins in mammary morphogenesis. The expression of the alpha 2 beta 1, alpha 3 beta 1 and alpha 6 beta 4 integrins was decreased when cells were plated on collagen gels. The addition of specific blocking monoclonal antibodies directed to the alpha 2- and beta 1-integrin subunits to growth media impaired cell-cell interactions and interfered with the formation of compact structures inside collagen gels, suggesting that the alpha 2 beta 1 integrin can control intercellular adhesion in mammary morphogenesis. In contrast one of the blocking monoclonal antibodies against the alpha 3-integrin subunit (P1B5) mimicked the effect of soluble 'morphogens'. Our results suggest that the modulation of alpha 3 beta 1 activity may represent an important event in the induction of branching morphogenesis of human mammary epithelial cells.
Berdichevsky
F
F
Imperial Cancer Research Fund, London, UK.
Alford
D
D
D'Souza
B
B
Taylor-Papadimitriou
J
J
D000818:Animals; D015703:Antigens, CD; D000954:Antigens, Surface; D001483:Base Sequence; D001940:Breast / Q000166:cytology* / Q000187:drug effects / Q000254:growth & development*; D002448:Cell Adhesion; D002478:Cells, Cultured; D003094:Collagen; D046508:Culture Techniques / Q000379:methods; D004847:Epithelial Cells; D004848:Epithelium / Q000254:growth & development; D005260:Female; D005782:Gels; D006133:Growth Substances / Q000494:pharmacology*; D017228:Hepatocyte Growth Factor / Q000494:pharmacology; D006801:Humans; D039201:Integrin alpha3beta1; D039161:Integrin alpha6beta4; D019012:Integrin beta1; D016023:Integrins; D008297:Male; D051379:Mice; D008969:Molecular Sequence Data; D009024:Morphogenesis
D015703:Antigens, CD; D000954:Antigens, Surface; D005782:Gels; D006133:Growth Substances; D039201:Integrin alpha3beta1; D039161:Integrin alpha6beta4; D019012:Integrin beta1; D016023:Integrins; D017228:Hepatocyte Growth Factor; D003094:Collagen